Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q4 FY19 results · Jan–Mar 2019
Marksans Pharma reported revenue from operations of ₹247.41 crore and net profit of ₹9.85 crore for Q4 FY19 (Jan–Mar 2019), on a consolidated basis.
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 247.41 | — | — | 248.37 | −0.4% |
| Other income | 9.73 | — | — | 0.16 | 62x |
| Total income | 257.14 | — | — | 248.52 | +3.5% |
| Profit before tax | 16.68 | — | — | 29.55 | −43.6% |
| Net profit for the period | 9.85 | — | — | 25.13 | −60.8% |
| Attributable to shareholders of the company | 8.51 | — | — | — | — |
| EPS, basic (₹) | 0.21 | — | — | 0.60 | −65.0% |
| Net margin (%) | 4.0 | — | 10.1 |
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 91.18 | — | — | 125.19 | −27.2% |
| Other income | 9.50 | — | — | 0.12 | 81x |
| Total income | 100.69 | — | — | 125.31 | −19.6% |
| Profit before tax | 8.82 | — | — | 13.98 | −36.9% |
| Net profit for the period | 5.62 | — | — | 11.78 | −52.3% |
| EPS, basic (₹) | 0.14 | — | — | 0.29 | −51.7% |
| Net margin (%) | 6.2 | — | 9.4 |
Consolidated
- Filed with BSE
- 06 Jun 2019, 12:00 IST
- Board meeting
- 29 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Jun 2019, 12:00 IST
- Board meeting
- 29 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE